Medtronic: independent panel confirms Endeavor's low thrombosis rate at TCT stent safety session

By Lisa Kerner

Charlotte, N.C., Oct. 24 - Medtronic, Inc. said data reviewed by an independent physician panel confirms that its Endeavor drug-eluting stent has a very low rate of stent thrombosis, 0.5% by Kaplan-Meier survival estimates to three years, compared to 1.4% for its Driver bare metal stent.

The physician panel plans to present its findings in a special drug-eluting stent safety session at the Cardiovascular Research Foundation's 18th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

"The data on Endeavor shows that it provides the efficacy of a drug-eluting stent and the safety of a bare metal stent, dramatically reducing repeat procedures while maintaining a favorable safety profile," president of Medtronic's vascular business Scott Ward said in a news release.

The Minneapolis-based medical technology company voluntarily subjected its clinical data to the blinded, retrospective analysis after new definitions for stent thrombosis were created by the Academic Research Corp.

Medtronic also announced the findings of a composite analysis of all cause death and Q-wave myocardial infarction data from the Endeavor I-III clinical trials which showed Endeavor has a lower composite death/QMI rate (2.2%) at two years compared to the Driver bare metal stent (3.1%).

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.